NDAINJECTIONINJECTABLE
Approved
Jun 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ARGATROBAN (argatroban) by Novartis is site. Approved for heparin-induced thrombocytopenia, thrombosis. First approved in 2000.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Argatroban is a small-molecule direct thrombin inhibitor administered by injection for treatment of heparin-induced thrombocytopenia (HIT) and associated thrombosis. It works by directly inhibiting both free and clot-bound thrombin without requiring antithrombin III as a cofactor, blocking fibrin formation and platelet aggregation.
LOE Approaching
As LOE approaches, brand positions are consolidating with multiple generic manufacturers at peak lifecycle; expect staffing rationalization and shift toward efficiency and compliance roles.
Mechanism of Action
site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C;…
Indications (2)
Worked on ARGATROBAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.